甲状腺素联合厄贝沙坦氢氯噻嗪治疗高龄重症心力衰竭

Thyroxine Combined With Irbesartan Hydrochlorothiazide in the Treatment of Elderly Patients With Severe Heart Failure

目的探讨高龄重症心力衰竭患者行甲状腺素以及厄贝沙坦氢氯噻嗪的临床治疗效果。方法选取我院于2016年3月—2017年3月所收治的高龄重症心力衰竭患者共60例作为研究对象。采用随机数字表法,将其平均分为研究组与对照组,每组各30例。两组患者均行基础治疗,研究组在此基础上,加行厄贝沙坦氢氯噻嗪联合小剂量甲状腺激素药物治疗,对比两组患者治疗后的临床指标以及总有效率。结果研究组与对照组治疗前的T3、T4以及LVEF等指标对比,差异不具有统计学意义(P> 0.05);经过治疗后,研究组患者的上述指标分别为(1.05±0.11)mmol/L、(117.94±12.07)mmol/L以及(52.31±3.91)%,对照组分别为(0.81±0.12)mmol/L、(95.60±13.44)mmol/L以及(45.96±3.63)%,组间对比,差异具有统计学意义(P <0.05)。两组患者治疗一个疗程后总有效率对比,研究组总有效率为93.3%,对照组为70.0%,两组比较,差异具有统计学意义(P <0.05)。结论通过小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭患者的临床治疗效果显著,临床心功能分级改善程度显著。

Objective To investigate the clinical efficacy of thyroxine and irbesartan hydrochlorothiazide in elderly patients with severe heart failure. Methods A total of 60 elderly patients with severe heart failure admitted to our hospital from March 2016 to March 2017 were selected as subjects. Using random number table method, the average was dividedinto the study group and the control group, 30 cases in each group. The two groups were treated with basic treatment. On this basis, the study group was given irbesartan hydrochlorothiazide combined with low-dose thyroid hormone therapy. The clinical indicators and total effective rate of the two groups after treatment were compared. Results T3, T4 and LVEF were not significantly different between the study group and the control group before treatment （P 〉 0.05）. After treatment, the above indexes in the study group were （1.05±0.11） mmol/L, （117.94±12.07） mmol/L and （52.31±3.91）% respectively, and those in the control group were （0.81±0.12） mmol/L, （95.60±13.44） mmol/L and （45.96±3.63） mmol/L, respectively. The difference was statistically signifcant （P 〈 0.05）. The total effective rate was 93.3% in the study group and 70.0% in the control group. The difference between the two groups was statistically signifcant （P 〈 0.05）. Conclusion The therapeutic effect of low dose thyroxine combined with erbesartan hydrochlorothiazide is significant in the treatment of elderly patients with severe heart failure, and the improvement of clinical cardiac function classifcation is signifcant.